<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6775">Mesalamine</z:chebi> (<z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi>; <z:chebi fb="0" ids="6775">5-ASA</z:chebi>) represents the cornerstone of first-line therapy for mild-to-moderate <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) </plain></SENT>
<SENT sid="1" pm="."><plain>Current guidelines suggest that the combination of oral and rectal therapies provide optimal symptom resolution and effectively maintain remission in the majority of these patients </plain></SENT>
<SENT sid="2" pm="."><plain>Although effective, most oral <z:chebi fb="0" ids="6775">5-ASA</z:chebi> formulations have a high pill burden and rectal therapies are associated with low adherence </plain></SENT>
<SENT sid="3" pm="."><plain>Recent research has examined patterns of compliance, as well as the efficacy of different dose levels of <z:chebi fb="0" ids="6775">5-ASA</z:chebi> in terms of symptom resolution, the maintenance of remission, and improvements in quality of life </plain></SENT>
<SENT sid="4" pm="."><plain>The ASCEND I, II, and III trials found that doses of 4.8 g/day are more effective than 2.4 g/day doses in patients with moderate disease, those with previous steroid use, and those with a history of multiple medications </plain></SENT>
<SENT sid="5" pm="."><plain>The benefits of effective long-term <z:chebi fb="0" ids="6775">5-ASA</z:chebi> therapy include the avoidance of more costly and potentially toxic drugs (such as <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and biologic therapies), as well as improvements in quality of life, reductions in the need for future colectomy, and a lower risk of developing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>